Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued to investors on Monday, October 28th. Leerink Partnrs analyst A. Berens now anticipates that the biopharmaceutical company will post earnings of ($7.32) per share for the year, up from their prior estimate of ($7.43). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($4.87) per share. Leerink Partnrs also issued estimates for Agios Pharmaceuticals' FY2026 earnings at ($6.81) EPS.

Several other equities research analysts have also issued reports on AGIO. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Leerink Partners lowered shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, October 16th. Raymond James restated an "outperform" rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Scotiabank started coverage on shares of Agios Pharmaceuticals in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $51.00 price objective for the company. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $52.00.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded down $0.53 during mid-day trading on Wednesday, hitting $46.30. 375,801 shares of the company's stock traded hands, compared to its average volume of 690,266. Agios Pharmaceuticals has a 1 year low of $20.35 and a 1 year high of $53.28. The company's 50-day moving average is $44.68 and its two-hundred day moving average is $42.01. The company has a market capitalization of $2.63 billion, a P/E ratio of -7.33 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business had revenue of $8.60 million for the quarter, compared to analysts' expectations of $9.34 million. During the same period in the previous year, the company earned ($1.51) EPS. Agios Pharmaceuticals's revenue for the quarter was up 28.4% compared to the same quarter last year.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the business's stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Brian Goff sold 11,091 shares of the firm's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of the business's stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.93% of the company's stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $37,000. Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC boosted its stake in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $216,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.